This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Miller, K. D. Articles by Sledge, G. W. Search for Related Content PubMed PubMed Citation Articles by Miller, K. D. Articles by Sledge, G. W.

A Randomized Phase II Feasibility Trial of BMS-275291 in Patients with Early Stage Breast Cancer

¹ Indiana University, Indianapolis, Indiana; ² Green Bay Oncology, Green Bay, Wisconsin; ³ Oncology/Hematology Care, Cincinnati, Ohio; ⁴ Bristol-Myers Squibb, New York, New York; ⁵ Albert Einstein University, Bronx, New York; ⁶ Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland; and ⁷ Rush Presbyterian St. Luke’s Medical Center, Chicago, Illinois

Purpose: This pilot trial was performed to evaluate the safety, pharmacokinetics and feasibility of incorporating BMS-275291, a matrix metalloproteinase inhibitor (MMPI), into adjuvant breast cancer therapy.

Experimental Design: Patients with stage I (T1c)-IIIA breast cancer were eligible if planned adjuvant therapy consisted of either tamoxifen alone, doxorubicin + cyclophosphamide every 21 days for four cycles (AC), or AC followed by paclitaxel every 21 days for 4 cycles (AC>T). Patients were stratified by planned adjuvant therapy and randomized (2:1 ratio) to BMS-275291 (1200 mg/day) or matched placebo for 1 year.

Results: Seventy-two patients were recruited from March 2001 to July 2002. Grade 2 musculoskeletal toxicity, generally reversible arthralgia, was reported by 36.2% of patients receiving BMS-275291 compared with 16.7% of patients receiving placebo; difference = 19.5% (95% confidence interval: -0.06, 0.44; P = NS). Two patients receiving BMS-275291 developed palpable nodules along tendons. Grade 3 rash was reported by 8.5% of patients receiving BMS-275291 compared with 4.2% of patients receiving placebo; difference = 4.3% (95% confidence interval: -0.18, 0.3; P = NS). Overall, 33% of BMS-275291 patients and 21% of placebo patients discontinued treatment due to adverse events. BMS-275291 trough levels tended to decrease over time; 9 of 47 (19%) had 50% of trough concentrations > 124 ng/ml (IC₉₀ for matrix metalloproteinase-9).

Conclusions: The pattern of arthralgia in BMS-275291-treated patients was consistent with matrix metalloproteinase inhibitor toxicity. Although the differential incidence of arthralgia did not reach statistical significance, the trial was terminated. An adjuvant trial in this patient population is not feasible.

This article has been cited by other articles:

				P. N. Lara Jr., W. M. Stadler, J. Longmate, D. I. Quinn, J. Wexler, M. Van Loan, P. Twardowski, P. H. Gumerlock, N. J. Vogelzang, E. E. Vokes, et al. A Randomized Phase II Trial of the Matrix Metalloproteinase Inhibitor BMS-275291 in Hormone-Refractory Prostate Cancer Patients with Bone Metastases Clin. Cancer Res., March 1, 2006; 12(5): 1556 - 1563. [Abstract] [Full Text] [PDF]

				E. Rosenbaum, M. Zahurak, V. Sinibaldi, M. A. Carducci, R. Pili, M. Laufer, T. L. DeWeese, and M. A. Eisenberger Marimastat in the Treatment of Patients with Biochemically Relapsed Prostate Cancer: A Prospective Randomized, Double-Blind, Phase I/II Trial Clin. Cancer Res., June 15, 2005; 11(12): 4437 - 4443. [Abstract] [Full Text] [PDF]

				N. B. Leighl, L. Paz-Ares, J.-Y. Douillard, C. Peschel, A. Arnold, A. Depierre, A. Santoro, D. C. Betticher, U. Gatzemeier, J. Jassem, et al. Randomized Phase III Study of Matrix Metalloproteinase Inhibitor BMS-275291 in Combination With Paclitaxel and Carboplatin in Advanced Non-Small-Cell Lung Cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18 J. Clin. Oncol., April 20, 2005; 23(12): 2831 - 2839. [Abstract] [Full Text] [PDF]